Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.

Julia Foldi,Adriana Kahn,Andrea Silber,Tao Qing,Emily Reisenbichler,Neal Fischbach,Justin Persico,Kerin Adelson,Anamika Katoch,Anees Chagpar,Tristen Park, Adam Blanchard,Kim Blenman,David L Rimm,Lajos Pusztai

Clinical cancer research : an official journal of the American Association for Cancer Research（2022）

引用 1|浏览13

暂无评分

摘要

pCR rates, 3-year OS and EFS after neoadjuvant immunotherapy and chemotherapy were similar in AA and non-AA patients. Toxicities, including the frequency of irAEs, were also similar.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要